NeoMatrix Announces Positive Topline Phase 1 Data for NMT-cP12
- Novel Peptide to Advance to Phase 2 for the Treatment of Severe Burns -
top of page
News
Search
Oct 30, 2017
NeoMatrix Therapeutics Enters Clinical Stage as IND for NMT-cP12 Goes Into Effect
- Potential First-in-Class Treatment for Serious Burn Injuries Targets PDGF -
bottom of page